ArticlePloS one2015
Antigenic Relatedness of Norovirus GII.4 Variants Determined by Human Challenge Sera.
Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Sustained persistence of blockade antibodies against emerging GII.4 and GII.17 noroviruses revealed by a 5-year community-based serological study.Frontiers in cellular and infection microbiology · 2026Article
- Interferons and tuft cell numbers are bottlenecks for persistent murine norovirus infection.PLoS pathogens · 2024Article
- Article
- Protein Nucleotidylylation in +ssRNA Viruses.Viruses · 2021Review
- Serological surveillance of noroviruses in a community-based prospective cohort: a study protocol.BMJ open · 2021Article
- Virus Etiology, Diversity and Clinical Characteristics in South African Children Hospitalised with Gastroenteritis.Viruses · 2021Article
- Evolutionary Mechanism of Immunological Cross-Reactivity Between Different GII.17 Variants.Frontiers in microbiology · 2021Article
- Characterization of a hospital-based gastroenteritis outbreak caused by GII.6 norovirus in Jinshan, China.Epidemiology and infection · 2020Article
- Structural and Antiviral Studies of the Human Norovirus GII.4 Protease.Biochemistry · 2019Article
- Environmental Surveillance for Noroviruses in Selected South African Wastewaters 2015-2016: Emergence of the Novel GII.17.Food and environmental virology · 2018Article
- Characterization of Antigenic Relatedness between GII.4 and GII.17 Noroviruses by Use of Serum Samples from Norovirus-Infected Patients.Journal of clinical microbiology · 2017Article
- Characterisation of a household norovirus outbreak occurred in Valencia (Spain).BMC infectious diseases · 2016Article
- An outbreak caused by GII.17 norovirus with a wide spectrum of HBGA-associated susceptibility.Scientific reports · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
The GII.4 noroviruses (NoVs) are a single genotype that is responsible for over 50% of NoV gastroenteritis epidemics worldwide. However, GII.4 NoVs have been found to undergo antigenic drifts, likely selected by host herd immunity, which raises an issue for vaccine strategies against NoVs. We previously characterized GII.4 NoV antigenic variations and found significant levels of antigenic relatedness among different GII.4 variants. Further characterization of the genetic and antigenic relatedness of recent GII.4 variants (2008b and 2010 cluster) was performed in this study. The amino acid sequences of the receptor binding interfaces were highly conserved among all GII.4 variants from the past two decades. Using serum samples from patients enrolled in a GII.4 virus challenge study, significant cross-reactivity between major GII.4 variants from 1998 to 2012 was observed using enzyme-linked immunosorbent assays and HBGA receptor blocking assays. The overall abilities of GII.4 NoVs to bind to the A/B/H HBGAs were maintained while their binding affinities to individual ABH antigens varied. These results highlight the importance of human HBGAs in NoV evolution and how conserved antigenic types impact vaccine development against GII.4 variants.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.